Key result
Early ACE inhibitors or ARBs fail to reduce M-CSF levels after acute MI.
Why the study?
The effects of early administration of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker on circulating macrophage colony-stimulating factor levels in acute myocardial infarction patients were unclear.
Does early administration of perindopril or candesartan reduce circulating macrophage colony-stimulating factor levels in patients with acute myocardial infarction?
RCT
Randomized
Does early administration of perindopril or candesartan reduce circulating macrophage colony-stimulating factor levels in patients with acute myocardial infarction?
Early inhibition of the renin-angiotensin system with perindopril or candesartan does not affect the elevated circulating macrophage colony-stimulating factor levels in patients with acute myocardial infarction.
Early RAS inhibition does not alter elevated M-CSF in acute MI; leaves open M-CSF as a therapeutic target.
Macrophage colony-stimulating factor, which induces proliferation and differentiation, and activation of monocytes and macrophages, plays an important role in the vulnerability of atheromatous plaques as well as the formation of atherosclerotic lesions. We measured serum concentrations of macrophage colony-stimulating factor in patients with acute myocardial infarction and also investigated the effects of early administration of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker on circulating macrophage colony-stimulating factor levels in these patients. The patients were divided randomly into 3 therapeutic groups; perindopril, candesartan, and control (without perindopril and candesartan) groups, and the drugs were administered within 24 to 36 hours after the onset of acute myocardial infarction. Serum macrophage colony-stimulating factor concentrations in acute myocardial infarction patients at the time of admission were significantly higher than those in healthy control subjects. The macrophage colony-stimulating factor levels in the patients decreased gradually after admission, but remained significantly higher than those in control subjects for 14 days. There were no significant differences in serum macrophage colony-stimulating factor levels among the 3 therapeutic groups during this study period. In conclusion, circulating macrophage colony-stimulating factor levels are elevated during the course of acute myocardial infarction, and inhibition of the renin-angiotensin system by angiotensin-converting enzyme inhibitor or angiotensin receptor blocker does not affect these levels.
No takes yet. Share an insight, caveat, or question.
Kurosaki et al. (2003) conducted an RCT in Acute myocardial infarction. Perindopril or candesartan vs. Control (without perindopril and candesartan) was evaluated on Serum macrophage colony-stimulating factor levels. Early administration of an ACE inhibitor (perindopril) or ARB (candesartan) did not significantly affect circulating macrophage colony-stimulating factor levels in patients with acute myocardial infarction.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: